What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 3).

What question did this study set out to answer?

This research aimed to evaluate the effectiveness of an AI-powered clinical trial patient matching system in increasing patient enrollment.

December 8, 2025BloodOpen Access

Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

JLJessica LiuBoston Children's Hospital AIAbel IncoomCommunity Health Alliance MSMaximilian StahlHarvard University

Discussion

Member takes

Implication

Evaluation reveals the AI patient matching tool improves accrual in myelodysplastic syndromes and myeloma trials, indicating potential for broader use.

Key Points

This research aimed to evaluate the effectiveness of an AI-powered clinical trial patient matching system in increasing patient enrollment.
Implemented AI-powered Clinical Trial Patient Matching across 13 cancer center sites
Analyzed data from approximately 74,000 patients weekly for two trials
Manually reviewed identified patients for eligibility before outreach.
CTPM identified 216 patients for MDS trial, with 11 deemed eligible; only 1 enrolled.
In the myeloma trial, CTPM identified 147 patients, with 10 eligible and 5 enrolling.
Accrual improved significantly from one patient every 2.6 months to one every 1.5 months due to CTPM implementation.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd47 https://doi.org/10.1182/blood-2025-1086

View Full Paper

Ask AI

Bookmark

Implication

Evaluation reveals the AI patient matching tool improves accrual in myelodysplastic syndromes and myeloma trials, indicating potential for broader use.

Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Prospective evaluation of an AI-powered clinical trial patient matching (CTPM) system in myelodysplastic syndromes (MDS) and multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider